Related Experiment Video

Updated: May 20, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review

Venkat Koushik Pulla1, Madhu Babu Battu, Mallika Alvala

  • 1Birla Institute of Technology & Science- Pilani, Hyderabad Campus, Department of Pharmacy, Drug Discovery Research Laboratory, R.R. District-500078, Andhra Pradesh, India.

Expert Opinion on Therapeutic Targets
|July 6, 2012
PubMed
Abstract

Insights

SIRT1 activators show promise for treating type 2 diabetes by improving insulin secretion and glucose metabolism. Ongoing research is clarifying SIRT1

Area of Science:

  • Metabolic pathways
  • Endocrinology
  • Molecular biology

Background:

  • Type 2 diabetes (T2DM) arises from metabolic pathway dysregulation and insulin resistance, a significant global health issue.
  • Imbalances in energy homeostasis disrupt normal metabolic functions, leading to hyperglycemia.
  • Insulin resistance is a hallmark of T2DM, contributing to elevated blood glucose levels.

Purpose of the Study:

  • To review advances in SIRT1 activation as a therapeutic strategy for type 2 diabetes over the past decade.
  • To discuss the safety and efficacy of SIRT1 activation in human diseases.
  • To elucidate the complex interplay between SIRT1, metabolic pathways, and T2DM across various tissues.

Main Methods:

  • Literature review summarizing research on SIRT1 and T2DM.
  • Analysis of SIRT1's role in insulin secretion, glucose uptake, and cellular processes.
  • Examination of SIRT1's metabolic functions in pancreas, skeletal muscle, adipose tissue, and liver.

Main Results:

  • SIRT1 is a key regulator of insulin secretion and glucose metabolism.
  • SIRT1 activation is being investigated as a potential treatment for T2DM.
  • Research has identified crucial intermediaries in metabolic tissues linked to SIRT1 and T2DM.

Conclusions:

  • Despite pathway complexity, SIRT1's role in T2DM metabolism is increasingly understood.
  • Targeting SIRT1 pathways offers future therapeutic prospects for type 2 diabetes.
  • Continued research is refining our understanding of SIRT1's impact on metabolic homeostasis in T2DM.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.